Cytokine-mediated obesity stimulates intestinal cancer

Share This Post

A new study describes themechanistic relationship between thecytokine interleukin-1β(IL-1β) and obesity. WhenIL-1βlevels increase in obesity, theactivation ofIL-1receptor signaling leads to a large number of colon cancers. Kinds of ways. This study shows that obesity is related tothe systemic increase ofIL-1β,the  activation ofWntand the proliferation of mouse colon cells.

Joel Mason of Tufts University in Massachusetts and Tufts University School of Medicine and colleagues at Tufts University co-authored the article ” Interleukin- 1 Signaling Mediates Obesity-Promoted Increased Inflammatory Cytokines, Wnt Activation, and Small ” Proliferation of rat colonic epithelial cells ” article. “

The researchers set out to determine the role of IL-1β in regulating events leading to obesity-promoting colorectal cancer. They compared the role of IL-1β in mice fed a high-fat (obese) or low-fat (lean) diet. One of the changes they are found in obese mice having colon mucosa 30-80 % higher concentration of IL-l [beta] , the Wnt cascade significantly increased signal amplification and significantly proliferating crypts in the colon region.

“This study reveals the close link between obesity and inflammatory response, and reflects the extensive role of IL-1β , defining obesity as one of many inflammatory diseases, ” Department of Immunology , Washington University, Center for Innate Immunity and Immune Diseases. Michael Gale Jr. , editor-in-chief of Journal of Interferon & Cytokine Research, said.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy